Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHST NASDAQ:MRNS NYSE:PLX NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$7.05-1.8%$6.74$4.66▼$7.86$115.80M0.6515,446 shs7,867 shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.88 million shs260 shsPLXProtalix BioTherapeutics$1.42+0.7%$1.64$0.82▼$3.10$113.04M-0.23591,997 shs419,188 shsUPXIUpexi$5.96+10.6%$8.79$1.90▼$22.57$225.97M-0.581.25 million shs8.48 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences0.00%+4.06%-0.28%+21.69%+717,999,900.00%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-59.92%PLXProtalix BioTherapeutics0.00%-8.74%-5.37%-46.18%+23.68%UPXIUpexi0.00%+65.08%-46.15%+99.63%-39.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/AMRNSMarinus Pharmaceuticals2.0682 of 5 stars3.20.00.04.20.01.70.6PLXProtalix BioTherapeutics2.8274 of 5 stars3.53.00.00.02.00.01.9UPXIUpexi2.6304 of 5 stars3.51.00.00.02.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 3.00Buy$13.6793.85% UpsideMRNSMarinus Pharmaceuticals 2.40Hold$3.92613.29% UpsidePLXProtalix BioTherapeutics 3.00Buy$15.00956.34% UpsideUPXIUpexi 3.00Buy$16.00168.46% UpsideCurrent Analyst Ratings BreakdownLatest MRNS, UPXI, PLX, and BHST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/16/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$16.005/5/2025BHSTBioHarvest SciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$27.70M4.18N/AN/A$0.08 per share88.13MRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77PLXProtalix BioTherapeutics$59.76M1.89$0.08 per share17.80$0.47 per share3.02UPXIUpexi$16.56M13.64N/AN/A$6.24 per share0.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$12.91M-$0.50N/AN/AN/A-31.30%-307.04%-33.21%8/14/2025 (Estimated)MRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)PLXProtalix BioTherapeutics$8.31M$0.04N/A4.58N/A-21.03%-30.89%-11.74%N/AUPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%9/22/2025 (Estimated)Latest MRNS, UPXI, PLX, and BHST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/15/2025Q1 2025BHSTBioHarvest Sciences-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million5/9/2025Q1PLXProtalix BioTherapeuticsN/A-$0.05N/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/APLXProtalix BioTherapeuticsN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest SciencesN/A0.510.30MRNSMarinus PharmaceuticalsN/A1.661.47PLXProtalix BioTherapeuticsN/A1.981.27UPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/AMRNSMarinus Pharmaceuticals98.80%PLXProtalix BioTherapeutics16.53%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/AMRNSMarinus Pharmaceuticals5.46%PLXProtalix BioTherapeutics6.50%UPXIUpexi31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A16.43 millionN/AN/AMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionablePLXProtalix BioTherapeutics20079.61 million69.00 millionOptionableUPXIUpexi13037.92 million25.93 millionOptionableMRNS, UPXI, PLX, and BHST HeadlinesRecent News About These CompaniesUpexi, Inc. Announces Pricing of $200 Million Concurrent Private ...July 13 at 6:19 PM | seekingalpha.comUpexi raises $200M to boost its Solana treasuryJuly 12 at 9:34 AM | msn.comUpexi prices $200M private placement of common stock and convertible notesJuly 11 at 8:13 PM | msn.comSOL: Nasdaq-Listed Firm Secures $200M in Financing, with Over $150M Tied to Solana Treasury StrategyJuly 11 at 8:13 PM | finance.yahoo.comUpexi, Inc. Announces Pricing of $200 Million Concurrent Private Placement of Common Stock and Convertible Notes both Priced above the At-the-Market Price under Nasdaq RulesJuly 11 at 8:30 AM | globenewswire.comUpexi (NASDAQ:UPXI) Trading 26.7% Higher - Time to Buy?July 9, 2025 | marketbeat.comUpexi, Inc. (UPXI) Latest Stock News & Headlines - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening Bell | MorningstarJune 27, 2025 | morningstar.comMUpexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell Platform - NasdaqJune 27, 2025 | nasdaq.comSolana-Focused Upexi to Tokenize Shares; Added 56K SOL to HoldingsJune 26, 2025 | finance.yahoo.comUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate’s Opening BellJune 26, 2025 | theglobeandmail.comUpexi, Inc. Announces Intention to Tokenize SEC-Registered Shares Using Superstate's Opening Bell PlatformJune 26, 2025 | quiverquant.comQUpexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate's Opening BellJune 26, 2025 | globenewswire.comSolana Treasury Firm Upexi Falls After Insider Sales FilingJune 25, 2025 | bloomberg.comNews Explorer — Crypto Treasury Chaos: Why Ethereum's SBET and Solana's UPXI Plunged After Routine SEC FilingsJune 25, 2025 | decrypt.coDUpexi stock plunges after filing allows investors to sell sharesJune 24, 2025 | in.investing.comUpexi’s Solana treasury backfires with 60%+ dip as 43 million shares hit open marketJune 24, 2025 | msn.comSOL Drops Below $150 After Sell-Off Despite Growing Institutional Adoption NarrativeJune 17, 2025 | coindesk.comUpexi, Inc. CSO Brian Rudick to Speak at ICR Conference on Public Market Crypto StrategiesJune 17, 2025 | quiverquant.comQUpexi's Chief Strategy Officer to Present at The ICR Conference Spotlight Series on June 20thJune 17, 2025 | globenewswire.comUpexi, Inc. (NASDAQ:UPXI) Sees Large Growth in Short InterestJune 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMRNS, UPXI, PLX, and BHST Company DescriptionsBioHarvest Sciences NASDAQ:BHST$7.05 -0.13 (-1.81%) As of 03:59 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Marinus Pharmaceuticals NASDAQ:MRNSMarinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.Protalix BioTherapeutics NYSE:PLX$1.42 +0.01 (+0.71%) Closing price 04:00 PM EasternExtended Trading$1.45 +0.03 (+1.83%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.Upexi NASDAQ:UPXI$5.96 +0.57 (+10.58%) Closing price 04:00 PM EasternExtended Trading$5.95 -0.01 (-0.10%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Insider Selling Hits Market Leaders—Should You Be Worried? MP Materials Stock Booms on New Government Positioning Tilray Shares Blazing: What's Behind the 55% Rally This Month? MarketBeat Week in Review – 07/07 - 07/11 How Texas Roadhouse Is Winning in a Changing Consumer Market Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
